This review update (original version published 25 June 2020) examines antibody tests for identification of current and past infection with SARS‐CoV‐2
The combination of nirmatrelvir with ritonavir (Paxlovid®) is a new medicine developed to treat infection with the SARS‐CoV‐2 virus and aims to avoid severe COVID‐19 in people without symptoms, or those with mild symptoms. This new review assessed the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid®) plus standard of care compared to standard of care with or without placebo, or any other intervention for treating COVID‐19 and for preventing SARS‐CoV‐2 infection
This is the third iteration of this Cochrane living review summarising the accuracy of point‐of‐care antigen tests for detecting current SARS‐CoV‐2 infection. (original version published 26 August 2020).
COVID-19 and subsequent infodemic represents an unprecedented global challenge for evidence synthesis and guideline development. The authors present consolidated resources to facilitate trustworthy, rapid and equitable evidence synthesis, health technology assessments and guidelines for public health and clinical practice.